President Donald Trump vowed to impose tariffs on pharmaceuticals within two weeks. Eli Lilly, a leader in the industry, could be harmed by the move, but it is already preparing for it.

(Reuters) -Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

That could be bad news for leaders in this sector, including Eli Lilly (NYSE: LLY), the largest pharmaceutical company in the world by market cap. Should investors give up on the stock?

Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more than $90 billion in market cap in a single day. "We think the market ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes. By Rebecca Robbins and Gina Kolata Encouraging ...

Eli Lilly isn't done in developing new weight loss treatments. In fact, the best may still be to come, as it's working on a pill, which could be a game changer for the industry.

INDIANAPOLIS - Eli Lilly and Company (NYSE: LLY) has announced a series of executive leadership transitions aimed at bolstering the company’s growth trajectory, particularly in the U.S. and ...

President Donald Trump signed a new executive order aimed at boosting domestic drug manufacturing. The executive order comes ahead of the Trump administration's planned tariffs on pharmaceuticals ...

Patents, economies of scale, and a powerful distribution network support Eli Lilly’s wide moat. Lilly’s patent-protected drugs carry strong pricing power, which enables the firm to generate ...

April 23 (UPI) --Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs.

Ore Huiying / Bloomberg / Getty Images Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released Phase 3 trial results for its oral weight-loss drug that ...